Dalteparin
- Generic Name
- Dalteparin
- Brand Names
- Fragmin
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- S79O08V79F
- Background
Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000. LMWHs have a more pre...
- Indication
Dalteparin is used as a prophylaxis for deep-vein thrombosis and pulmonary embolisms in patients undergoing general surgery (e.g., abdominal, gynecologic, urologic), and in patients with acute medical conditions (e.g. cancer, bed rest, heart failure, severe lung disease). It is also used in patients who have severely restricted mobility, which poses a risk f...
- Associated Conditions
- Cardiovascular Events, Clotting, Deep Vein Thrombosis, Symptomatic Venous Thromboembolism, Venous Thromboembolism
- Associated Therapies
- -
Prophylaxis In Venous Thromboembolism In Primary Care, A Pilot Study
- Conditions
- Interventions
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2008-09-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8
- Registration Number
- NCT00655122
- Locations
- 🇪🇸
Pfizer Investigational Site, Torremolinos, Spain
Dalteparin in Preventing DVT in Participants With Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-09-05
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 65
- Registration Number
- NCT00525057
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Dalteparin in Preventing Blood Clots in Patients With Lung Cancer
- Conditions
- First Posted Date
- 2007-08-23
- Last Posted Date
- 2011-08-08
- Lead Sponsor
- Velindre NHS Trust
- Target Recruit Count
- 2200
- Registration Number
- NCT00519805
- Locations
- 🇬🇧
Royal Bournemouth Hospital, Bournemouth, England, United Kingdom
🇬🇧Burnley General Hospital, Burnley, England, United Kingdom
🇬🇧Nottingham City Hospital, Nottingham, England, United Kingdom
Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
- Conditions
- First Posted Date
- 2007-04-19
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Hull University Teaching Hospitals NHS Trust
- Target Recruit Count
- 120
- Registration Number
- NCT00462852
- Locations
- 🇬🇧
Saint Bartholomew's Hospital, London, England, United Kingdom
🇬🇧St. George's Hospital, London, England, United Kingdom
🇬🇧Nottingham City Hospital, Nottingham, England, United Kingdom
Thromboprophylaxis in Critically Ill Patients
- Conditions
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2007-02-21
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 90
- Registration Number
- NCT00437697
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
PERIOP 2 - A Safety and Effectiveness of LMWH vs Placebo Bridging Therapy for Patients on Long Term Warfarin Requiring Temporary Interruption of Warfarin.
- First Posted Date
- 2007-02-08
- Last Posted Date
- 2020-02-19
- Lead Sponsor
- Lawson Health Research Institute
- Target Recruit Count
- 1473
- Registration Number
- NCT00432796
- Locations
- 🇨🇦
Hamilton Health Sciences Corporation-Henderson Site, Hamilton, Ontario, Canada
🇮🇳Care Hospital, Hyderabad, Nampally, India
🇮🇳Sir Ganga Ram Hospital, New Delhi, India
LMWH to Prevent Preeclampsia and Fetal Growth Restriction
- Conditions
- First Posted Date
- 2005-12-01
- Last Posted Date
- 2006-03-06
- Lead Sponsor
- University of Florence
- Registration Number
- NCT00260520
Fragmin in Ovarian Cancer: Utility on Survival (FOCUS)
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2010-02-03
- Lead Sponsor
- Ontario Clinical Oncology Group (OCOG)
- Target Recruit Count
- 77
- Registration Number
- NCT00239980
- Locations
- 🇨🇦
Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada
🇨🇦B.C. Cancer Agency- Vancouver Centre, Vancouver, British Columbia, Canada
🇨🇦B.C. Cancer Agency- Fraser Valley Centre, Surrey, British Columbia, Canada
The Catheter Study: Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- Lawson Health Research Institute
- Target Recruit Count
- 70
- Registration Number
- NCT00216866
- Locations
- 🇨🇦
London Health Sciences Centre, London, Ontario, Canada
🇨🇦Queen Elizabeth II Health Care Centre, Halifax, Nova Scotia, Canada
🇨🇦St. Joseph's Healthcare, Hamilton, Ontario, Canada
Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients
- Conditions
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2007-04-27
- Lead Sponsor
- Ontario Clinical Oncology Group (OCOG)
- Target Recruit Count
- 512
- Registration Number
- NCT00135876
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦The Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada
🇦🇺Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.